Erratum: Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis (Drug Metabolism and Disposition (2009) 37 (1513-1520) DOI: 10.1124/dmd.109.026567);Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis

Drug Metabolism and Disposition

Volumn 37, Issue 7, 2009, Pages 1513-1520

  Watanabe, Akinobu ^a   Fukami, Tatsuki ^a   Nakajima, Miki ^a   Takamiya, Masataka ^b   Aoki, Yasuhiro ^b   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE ACYLTRANSFERASE; ACYLTRANSFERASE; BENZYLSULFONYL FLUORIDE; CARBOXYLESTERASE; CARBOXYLESTERASE 1A1; CARBOXYLESTERASE 1A2; CARBOXYLESTERASE 2; DISULFIRAM; DRUG METABOLIZING ENZYME; DYFLOS; ENZYME INHIBITOR; FLUORIDE SODIUM; FLUTAMIDE; FLUTAMIDE HYDROLASE; HYDROLASE; MESSENGER RNA; PHOSPHATE; PHYSOSTIGMINE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CONTROLLED STUDY; DRUG HYDROLYSIS; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME KINETICS; GENE EXPRESSION SYSTEM; HUMAN; HUMAN TISSUE; JEJUNUM; KIDNEY MICROSOME; LIVER CYTOSOL; LIVER MICROSOME; LUNG; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 67649411644     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.026567     Document Type: Erratum

References (37)

1. Aizawa Y, Ikemoto I, Kishimoto K, Wada T, Yamazaki H, Ohishi Y, Kiyota H, Furuta N, Suzuki H, and Ueda M (2003) Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites. Mol Cell Biochem 252:149-156. (Pubitemid 37220744)
2. Block W and Arndt R (1978) Chromatographic study on the specificity of bis-p-nitrophenylphosphate in vivo. Identification of labelled proteins of rat liver after intravenous injection of bis-p-nitro[14C]phenylphosphate as carboxylesterases and amidases. Biochim Biophys Acta 524:85-93.
3. Ciliv G and Ozand PT (1972) Human erythrocyte acetylcholinesterase purification, properties and kinetic behavior. Biochim Biophys Acta 284:136-156.
4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424. (Pubitemid 19211484)
5. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, and Pessayre D (1994) Toxicity of the antiandrogen flutamide I isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962. (Pubitemid 24204174)
6. Frick C, Atanasov AG, Arnold P, Ozols J, and Odermatt A (2004) Appropriate function of 11β-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase. J Biol Chem 279:31131-31138. (Pubitemid 39037775)
7. Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, and Yamazoe Y (2006) Detection of new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl) phenyl]hydroxylamide, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 34:828-835.
8. Gonzalvo MC, Gil F, Hernández AF, Villanueva E, and Pla A (1997) Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and merculials. Chem Biol Interact 105:169-179. (Pubitemid 27353307)
9. Heymann E and Krisch K (1967) Phospholic acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases. Hoppe Seylers Z Physiol Chem 348:609-619.
10. Imai T, Taketani M, Shii M, Hosokawa M, and Chiba K (2006) Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34:1734-1741. (Pubitemid 44427476)
11. Iwatsubo K (1965) Studies on the classification of the enzymes hydrolysing ester-form drugs in liver microsomes. Jpn J Pharmacol 15:244-265.
12. Johnson G and Moore SW (2000) Cholinesterase-like catalytic antibodies: reaction with substrates and inhibitors. Mol Immunol 37:707-719.
13. Katchen B and Buxbaum S (1975) Disposition of a new, nonsteroid, antiandrogen, alpha,alpha, alpha-trifluoro-2-methyl-4′-nitro-m- propionotoluidine (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41:373-379.
14. Labar G, Bauvois C, Muccioli GG, Wouters J, and Lambert DM (2007) Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem 8:1293-1297. (Pubitemid 47171996)
15. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
16. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158. (Pubitemid 29269980)
17. Matsuzaki Y, Nagai D, Ichimura E, Goda R, Tomura A, Doi M, and Nishikawa K (2006) Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J Gastroenterol 41:231-239.
18. Mentlein R, Rix-Matzen H, and Heymann E (1988) Subcellular localization of non-specific carboxylesterases, acylcarnitine hydrolase, monoacylglycerol lipase and palmitoyl-CoA hydrolase in rat liver. Biochim Biophys Acta 964:319-328. (Pubitemid 18084982)
19. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, and Yokoi T (2006) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526. (Pubitemid 44691304)
20. Ohbuchi M, Miyata M, Nagai D, Shimada M, Yoshinari K, and Yamazoe Y (2009) Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. Drug Metab Dispos 37:97-105.
21. Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, Yoshida K, Ichinei M, Yamashita T, and Hirao Y (2002) Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis 5:128-131. (Pubitemid 34777896)
22. Preuss CV and Svensson CK (1996) Arylacetamide deacetylase activity towards monoacetyldapsone. Biochem Pharmacol 51:1661-1668.
23. Probst MR, Beer M, Beer D, Jenö P, Meyer UA, and Gasser R (1994) Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylamine carcinogens with high sequence similarity to hormone-sensitive lipase. J Biol Chem 269:21650-21656. (Pubitemid 24274803)
24. Probst MR, Jenö P, and Meyer UA (1991) Purification and characterization of a human liver arylacetamide deacetylase. Biochem Biophys Res Commun 177:453-459.
25. Ross MK and Crow JA (2007) Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 21:187-196. (Pubitemid 350194379)
26. Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, and Nakamura Y (2003) Catalog of 680 variations among eight cytochrome P450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 48:249-270. (Pubitemid 36759488)
27. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, and Bosron WF (2004) Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 32:505-511. (Pubitemid 38535028)
28. Schulz M, Schmoldt A, Donn F, and Becker H (1988) The pharmacokinetics of flutamide and its metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 34:633-636. (Pubitemid 18185203)
29. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, and Yokoi T (2004) Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos 32:762-767. (Pubitemid 38821879)
30. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, and Hirano K (1997) Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 20:869-873. (Pubitemid 27382753)
31. Thole Z, Manso G, Salgueiro E, Revuelta P, and Hidalgo A (2004) Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 73:289-295. (Pubitemid 39664297)
32. Tiwari R, Köffel R, and Schneiter R (2007) An acetylation/ deacetylation cycle controls the export of sterols and steroids from. S. cerevisiae. EMBO J 26:5109-5119. (Pubitemid 350261287)
33. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, and Yokoi T (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 64:3119-3125. (Pubitemid 38581412)
34. Usui S, Kubota M, Iguchi K, Kiho T, Sugiyama T, Katagiri Y, and Hirano K (2003) Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril. Pharm Res 20:1309-1316. (Pubitemid 36957910)
35. Xie M, Yang D, Liu L, Xue B, and Yan B (2002) Human and rodent carboxylesterase: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab Dispos 30:541-547. (Pubitemid 34456976)
36. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irionotecan. Clin Cancer Res 8:2605-2611. (Pubitemid 34856347)
37. Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, et al. (2006) Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:147-155.